Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics Inc. (TTRX)
Company Research
Source: Business Wire
Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company’s lead investigational therapy LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company’s lead investigational therapy, GX-03, which is currently in Phase 2 clinical trials.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217871104/en/Dr. Robert Redfield“Dr. Redfield brings an incomparable level of experience, public health insight, and regulatory knowledge to the Turn ecosystem,” s
Show less
Read more
Impact Snapshot
Event Time:
TTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TTRX alerts
High impacting Turn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
TTRX
News
- Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdatesBusiness Wire
- Turn Therapeutics Secures $25M Financing for Dermatology Trials [Los Angeles Times (CA)]Los Angeles Times
- Turn Therapeutics (TTRX) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $8.00 price target on the stock.MarketBeat
- Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital GroupBusiness Wire
- Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences [Yahoo! Finance]Yahoo! Finance
TTRX
Sec Filings
- 4/6/26 - Form SCHEDULE
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- TTRX's page on the SEC website